Premature ejaculation also called as rapid ejaculation, premature climax or early ejaculation. It is a disorder, which causes early ejaculation of semen during sexual intercourse. Premature ejaculation is a very common problem, and its exact cause is not known. However, causes include early sexual experiences, sexual abuse, poor body image, depression, anxiety, abnormal hormone levels, inherited traits, inflammation and infection of the prostate or urethra, and worrying about premature ejaculation.
Increasing launches of novel products for the treatment of premature ejaculation is expected to fuel the global premature ejaculation treatment market growth. For instance, in 2016, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product, Fortacin in the U.K. Fortacin is a topical spray, which contains low doses of two anesthetics - lidocaine and prilocaine and is indicated for the treatment of premature ejaculation. Furthermore, increasing prevalence of premature ejaculation due to unhealthy lifestyle and various factors such as depression and hormonal imbalance is expected to rise demand for premature ejaculation treatment drugs. For instance, according to the data published by National Center for BioDrug Type Information in 2016, around 25.8% of male in China are suffering from premature ejaculation.
- This report provides in-depth analysis of premature ejaculation treatment market and provides market size (USD Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period (2026 – 2033), considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global premature ejaculation treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technological up-gradation, market expansion, and marketing tactics
- The global premature ejaculation treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the premature ejaculation treatment market
-
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Phosphodiesterase Type 5 (PDE5) Inhibitors
- Topical Anesthetics
- Others
-
-
-
- Hospitals
- Online Pharmacies
- Retail Pharmacies
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Regent Pacific Group Limited
- Menarini Group
- Furiex Pharmaceuticals, Inc.
- Absorption Pharmaceuticals, LLC
- Ampio Pharmaceuticals, Inc.
- Aytu BioScience,
- NeuroHealing Pharmaceuticals Inc.
- Dong-A Pharmaceutical Co., Ltd.
